首页> The Lancet. Infectious diseases> Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.

Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Vivek,Shinde

第一单位： Novavax, Gaithersburg, MD, USA. Electronic address: vshinde@novavax.com.

作者： Vivek,Shinde ^[1] ; Iksung,Cho ^[2] ; Joyce S,Plested ^[2] ; Sapeckshita,Agrawal ^[3] ; Jamie,Fiske ^[2] ; Rongman,Cai ^[4] ; Haixia,Zhou ^[2] ; Xuan,Pham ^[5] ; Mingzhu,Zhu ^[2] ; Shane,Cloney-Clark ^[2] ; Nan,Wang ^[2] ; Bin,Zhou ^[2] ; Maggie,Lewis ^[2] ; Patty,Price-Abbott ^[2] ; Nita,Patel ^[2] ; Michael J,Massare ^[2] ; Gale,Smith ^[2] ; Cheryl,Keech ^[2] ; Louis,Fries ^[2] ; Gregory M,Glenn ^[2]

作者单位： Novavax, Gaithersburg, MD, USA. Electronic address: vshinde@novavax.com. ^[1] Novavax, Gaithersburg, MD, USA. ^[2] Novavax, Gaithersburg, MD, USA; Assembly Biosciences, San Francisco, CA, USA. ^[3] Novavax, Gaithersburg, MD, USA; Parexel, Billerica, MA, USA. ^[4] Novavax, Gaithersburg, MD, USA; AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA. ^[5]